Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model

Journal of Controlled Release

Volumn 160, Issue 2, 2012, Pages 254-263

  Petersen, Anncatrine L ^a   Binderup, Tina ^b   Jolck, Rasmus I ^a   Rasmussen, Palle ^a   Henriksen, Jonas R ^a   Pfeifer, Andreas K ^b   Kjær, Andreas ^b   Andresen, Thomas L ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Liposomes; Nanoparticles; Octreotate; Positron emission tomography; Somatostatin; Targeting ligand

Indexed keywords

ACTIVE TARGETING; BIODISTRIBUTIONS; FUNCTIONALIZED; HIGHER T; IMAGING AGENT; IMAGING CAPABILITIES; MOUSE MODELS; NANOCARRIERS; NEUROENDOCRINE TUMORS; NON-TARGETED; OCTREOTATE; PEGYLATED LIPOSOMES; PEPTIDE ANALOGS; POSITRON EMITTERS; SOMATOSTATIN; SOMATOSTATIN RECEPTORS; TUMOR ACCUMULATION; TUMOR CELLS; TUMOR TISSUES;

DIAGNOSIS; DISEASES; LIGANDS; MAMMALS; NANOPARTICLES; PEPTIDES; POSITRON EMISSION TOMOGRAPHY; TUMORS;

LIPOSOMES;

LIPOSOME; NANOCARRIER; OCTREOTATE DOTA CU 64; PEGYLATED LIPOSOME; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CHEMICAL STRUCTURE; DIAGNOSTIC IMAGING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SCREENING; DRUG TARGETING; HALF LIFE TIME; HEART; HUMAN; IN VITRO STUDY; INTESTINE; ISOTOPE LABELING; KIDNEY; LIVER; LUNG; MOUSE; MUSCLE; NANOENCAPSULATION; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SPLEEN; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, NEUROENDOCRINE; CELL LINE, TUMOR; COPPER RADIOISOTOPES; FEMALE; HUMANS; ISOTOPE LABELING; LIPOSOMES; MICE; MICE, NUDE; MOLECULAR STRUCTURE; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PHOSPHATIDYLETHANOLAMINES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, SOMATOSTATIN; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861661506     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.12.038     Document Type: Article

References (33)

1. D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, and R. Langer Nanocarriers as emerging platform for cancer therapy Nat. Nanotechnol. 2 2007 751 760
2. Y. Barenholz Liposome application: problems and prospects Curr. Opin. Colloid In. 6 2001 66 77
3. T. Kaasgaard, and T.L. Andresen Liposomal cancer therapy: exploiting tumor characteristics Expert Opin. Drug Del. 7 2010 225 243
4. M.A. Phillips, M.L. Gran, and N.A. Peppas Targeted nanodelivery of drugs and diagnostics Nano today 5 2010 143 159
5. 64Cu loaded liposomes as positron emission tomography imaging agents Biomaterials 32 2011 2334 2341
6. F. Danhier, O. Feron, and V. Préat To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery J. Control. Release 148 2010 135 146
7. T.L. Andresen, S.S. Jensen, and K. Jorgensen Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release Prog. Lipid Res. 44 2005 68 97
8. J.W. Park, K. Hong, D.B. Kirpotin, G. Colbern, R. Shalaby, J. Baselga, Y. Shao, U.B. Nielsen, J.D. Marks, D. Moore, D. Papahadjopoulos, and C.C. Benz Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery Clin. Cancer Res. 8 2002 1172 1181
9. D.W. Bartlett, H. Su, I.J. Hildebrandt, W.A. Weber, and M.E. Davis Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging Proc. Natl. Acad. Sci. U. S. A. 104 2007 15549 15554
10. S. Dagar, A. Krishnadas, I. Rubinstein, M.J. Blend, and H. Önyüksel VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies J. Control. Release 91 2003 123 133
11. S. Gosk, T. Moos, C. Gottstein, and G. Bendas VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo Biochim. Biophys. Acta 1178 2008 854 863
12. R.M. Schiffelers, G.A. Koning, T.L.M. ten Hagen, M.H.A.M. Fens, A.J. Schraa, A.P.C.A. Janssen, R.J. Kok, G. Molema, and G. Storm Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin J. Control. Release 91 2003 115 122
13. 90Y-labeled nanoparticles Int. J. Radiat. Oncol. Biol. Phys. 58 2004 1215 1227
14. A. Gabizon, A.T. Horowitz, D. Goren, D. Tzemach, H. Shmeeda, and S. Zalipsky In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice Clin. Cancer Res. 9 2003 6551 6559
15. D.B. Kirpotin, D.C. Drummond, Y. Shao, M.R. Shalaby, K. Hong, U.B. Nielsen, K.D. Marks, C.C. Benz, and J.W. Park Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models Cancer Res. 66 2006 6732 6740
16. T.W. Phillips, and B. Goins Targeted delivery of imaging agents by liposomes V.P. Torchilin, Handbook of targeted delivery of imaging agents 1995 CRS Press Boca Raton 149 173
17. H.L. Watt, G. Kharmate, and U. Kumar Biology of somatostatin in breast cancer Mol. Cell. Endocrinol. 286 2008 251 261
18. Y.C. Patel, and C.B. Srikant Somatostatin receptors Trends Endocrinol. Metab. 8 1997 398 405
19. J.C. Reubi, J.-C. Schär, B. Waser, S. Wenger, A. Heppeler, J.S. Schmitt, and H.R. Mäcke Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use Eur. J. Nucl. Med. 27 2000 273 282
20. S. Froidevaux, A. Heppeler, A.N. Eberle, A.-M. Meier, M. Häusler, C. Beglinger, M. Béhé, P. Powell, and H.R. Mäcke Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy Endocrinology 141 2000 3304 3312
21. J.S. Lewis, R. Laforest, M.R. Lewis, and C.J. Anderson Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model Cancer Biother. Radiopharm. 15 2000 593 604
22. 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy Cancer Res. 58 1998 437 441
23. T. Binderup, U. Knigge, A.M. Mogensen, C.P. Hansen, and A. Kjaer Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors Neuroendocrinology 87 2008 223 232
24. S. Jonas, M. John, J. Boese-Landgraf, R. Häring, G. Prevost, F. Thomas, S. Rosewicz, E.O. Riecken, B. Wiedenmann, and P. Neuhaus Somatostatin receptor subtypes in neuroendocrine tumor cell lines and tumor tissues Langenbecks Arch. Chir. 380 1995 90 95
25. A. Gabizon, D.C. Price, J. Huberty, R.S. Bresalier, and D. Papahadjopoulos Effect of liposomes composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies Cancer Res. 50 1990 6371 6378
26. W.T. Phillips Delivery of gamma-imaging agents by liposomes Adv. Drug Deliv. Rev. 37 1999 13 32
27. 111In- DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies Br. J. Cancer 83 2000 232 238
28. J.C. Reubi, R. Maurer, K. von Werder, J. Torhorst, J.G.M. Klijn, and S.W.J. Lamberts Somatostatin receptors in human endocrine tumors Cancer Res. 47 1987 551 558
29. I. Virgolini, T. Pangerl, C. Bischof, P. Smith-Jones, and M. Peck-Radosavljevic Somatostatin receptor subtype expression in human tissues: a prediction for diagnosis and treatment of cancer? Eur. J. Clin. Invest. 27 1997 645 647
30. M.O. Oyewumi, R.A. Yokel, M. Jay, T. Coakley, and R.J. Mumper Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice J. Control. Release 95 2004 613 626
31. J. Zhang, W. Jin, X. Wang, J. Wang, X. Zhang, and Q. Zhang A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models Mol. Pharmaceut. 7 2010 1159 1168
32. F. Pastorino, C. Brignole, D. Marimpietri, M. Cilli, C. Gambini, D. Ribatti, R. Longhi, T.M. Allen, A. Corti, and M. Ponzoni Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy Cancer Res. 63 2003 7400 7409
33. 111In-labeled polychelating-polymer- containing immunoliposomes Mol. Pharm. 3 2006 525 530